全文获取类型
收费全文 | 124537篇 |
免费 | 7635篇 |
国内免费 | 1090篇 |
专业分类
耳鼻咽喉 | 1926篇 |
儿科学 | 1919篇 |
妇产科学 | 1877篇 |
基础医学 | 19898篇 |
口腔科学 | 3059篇 |
临床医学 | 11541篇 |
内科学 | 21976篇 |
皮肤病学 | 3958篇 |
神经病学 | 10179篇 |
特种医学 | 7184篇 |
外科学 | 16682篇 |
综合类 | 518篇 |
现状与发展 | 3篇 |
一般理论 | 27篇 |
预防医学 | 6449篇 |
眼科学 | 3130篇 |
药学 | 11346篇 |
中国医学 | 1459篇 |
肿瘤学 | 10131篇 |
出版年
2023年 | 664篇 |
2022年 | 477篇 |
2021年 | 4299篇 |
2020年 | 2108篇 |
2019年 | 2961篇 |
2018年 | 3694篇 |
2017年 | 3004篇 |
2016年 | 3917篇 |
2015年 | 5451篇 |
2014年 | 6458篇 |
2013年 | 7527篇 |
2012年 | 11293篇 |
2011年 | 10844篇 |
2010年 | 6205篇 |
2009年 | 5334篇 |
2008年 | 7582篇 |
2007年 | 7196篇 |
2006年 | 6504篇 |
2005年 | 6025篇 |
2004年 | 5253篇 |
2003年 | 4567篇 |
2002年 | 3938篇 |
2001年 | 3040篇 |
2000年 | 2796篇 |
1999年 | 2143篇 |
1998年 | 909篇 |
1997年 | 668篇 |
1996年 | 509篇 |
1995年 | 455篇 |
1994年 | 387篇 |
1993年 | 330篇 |
1992年 | 747篇 |
1991年 | 698篇 |
1990年 | 641篇 |
1989年 | 555篇 |
1988年 | 464篇 |
1987年 | 466篇 |
1986年 | 332篇 |
1985年 | 371篇 |
1984年 | 261篇 |
1983年 | 190篇 |
1982年 | 132篇 |
1981年 | 166篇 |
1980年 | 127篇 |
1979年 | 220篇 |
1978年 | 162篇 |
1976年 | 133篇 |
1975年 | 120篇 |
1974年 | 139篇 |
1973年 | 119篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
81.
Sanne C. F. A. Huijberts Robin M. J. M. van Geel Emilie M. J. van Brummelen Frans L. Opdam Serena Marchetti Neeltje Steeghs Saskia Pulleman Bas Thijssen Hilde Rosing Kim Monkhorst Alwin D. R. Huitema Jos H. Beijnen Ren Bernards Jan H. M. Schellens 《Cancer chemotherapy and pharmacology》2020,85(5):917-930
KRAS oncogene mutations cause sustained signaling through the MAPK pathway. Concurrent inhibition of MEK, EGFR, and HER2 resulted in complete inhibition of tumor growth in KRAS-mutant (KRASm) and PIK3CA wild-type tumors, in vitro and in vivo. In this phase I study, patients with advanced KRASm and PIK3CA wild-type colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and pancreatic cancer, were treated with combined lapatinib and trametinib to assess the recommended phase 2 regimen (RP2R). Patients received escalating doses of continuous or intermittent once daily (QD) orally administered lapatinib and trametinib, starting at 750 mg and 1 mg continuously, respectively. Thirty-four patients (16 CRC, 15 NSCLC, three pancreatic cancers) were enrolled across six dose levels and eight patients experienced dose-limiting toxicities, including grade 3 diarrhea (n = 2), rash (n = 2), nausea (n = 1), multiple grade 2 toxicities (n = 1), and aspartate aminotransferase elevation (n = 1), resulting in the inability to receive 75% of planned doses (n = 2) or treatment delay (n = 2). The RP2R with continuous dosing was 750 mg lapatinib QD plus 1 mg trametinib QD and with intermittent dosing 750 mg lapatinib QD and trametinib 1.5 mg QD 5 days on/2 days off. Regression of target lesions was seen in 6 of the 24 patients evaluable for response, with one confirmed partial response in NSCLC. Pharmacokinetic results were as expected. Lapatinib and trametinib could be combined in an intermittent dosing schedule in patients with manageable toxicity. Preliminary signs of anti-tumor activity in NSCLC have been observed and pharmacodynamic target engagement was demonstrated. 相似文献
82.
Mohamed E. Salem J. Nicholas Bodor Alberto Puccini Joanne Xiu Richard M. Goldberg Axel Grothey W. Michael Korn Anthony F. Shields William M Worrilow Edward S. Kim Heinz-Josef Lenz John L. Marshall Michael J. Hall 《International journal of cancer. Journal international du cancer》2020,147(10):2948-2956
Microsatellite instability-high (MSI-H) and tumor mutational burden (TMB) are predictive biomarkers for immune-checkpoint inhibitors (ICIs). Still, the relationship between the underlying cause(s) of MSI and TMB in tumors remains poorly defined. We investigated associations of TMB to mismatch repair (MMR) protein expression patterns by immunohistochemistry (IHC) and MMR mutations in a diverse sample of tumors. Hypothesized differences were identified by the protein/gene affected/mutated and the tumor histology/primary site. Overall, 1057 MSI-H tumors were identified from the 32 932 tested. MSI was examined by NGS using 7000+ target microsatellite loci. TMB was calculated using only nonsynonymous missense mutations sequenced with a 592-gene panel; a subset of MSI-H tumors also had MMR IHC performed. Analyses examined TMB by MMR protein heterodimer impacted (loss of MLH1/PMS2 vs. MSH2/MSH6 expression) and gene-specific mutations. The sample was 54.6% female; mean age was 63.5 years. Among IHC tested tumors, loss of co-expression of MLH1/PMS2 was more common (n = 544/705, 77.2%) than loss of MSH2/MSH6 (n = 81/705, 11.5%; P < .0001), and was associated with lower mean TMB (MLH1/PMS2: 25.03 mut/Mb vs MSH2/MSH6 46.83 mut/Mb; P < .0001). TMB also varied by tumor histology: colorectal cancers demonstrating MLH1/PMS2 loss had higher TMBs (33.14 mut/Mb) than endometrial cancers (20.60 mut/Mb) and other tumors (25.59 mut/Mb; P < .0001). MMR gene mutations were detected in 42.0% of tumors; among these, MSH6 mutations were most common (25.7%). MSH6 mutation patterns showed variability by tumor histology and TMB. TMB varies by underlying cause(s) of MSI and tumor histology; this heterogeneity may contribute to differences in response to ICI. 相似文献
83.
84.
85.
86.
87.
88.
89.
Eun-Joo Shin Yunsung Nam Thu-Hien Thi Tu Yong Kwang Lim Myung-Bok Wie Dae-Joong Kim Ji Hoon Jeong Hyoung-Chun Kim 《Archives of toxicology》2016,90(4):937-953
We investigated whether protein kinase C (PKC) is involved in trimethyltin (TMT)-induced neurotoxicity. TMT treatment (2.8 mg/kg, i.p.) significantly increased PKCδ expression out of PKC isozymes (i.e., α, βI, βII, δ, and ?) in the hippocampus of wild-type (WT) mice. Consistently, treatment with TMT resulted in significant increases in cleaved PKCδ expression. Genetic or pharmacological inhibition (PKCδ knockout or rottlerin) was less susceptible to TMT-induced seizures than WT mice. TMT treatment increased glutathione oxidation, lipid peroxidation, protein oxidation, and levels of reactive oxygen species. These effects were more pronounced in the WT mice than in PKCδ knockout mice. In addition, the ability of TMT to induce nuclear translocation of Nrf2, Nrf2 DNA-binding activity, and upregulation of γ-glutamylcysteine ligase was significantly increased in the PKCδ knockout mice and rottlerin (10 or 20 mg/kg, p.o. × 6)-treated WT mice. Furthermore, neuronal degeneration (as shown by nuclear chromatin clumping and TUNEL staining) in WT mice was most pronounced 2 days after TMT. At the same time, TMT-induced inhibition of phosphoinositol 3-kinase (PI3K)/Akt signaling was evident, thereby decreasing phospho-Bad, expression of Bcl-xL and Bcl-2, and the interaction between phospho-Bad and 14-3-3 protein, and increasing Bax expression and caspase-3 cleavage were observed. Rottlerin or PKCδ knockout significantly protected these changes in anti- and pro-apoptotic factors. Importantly, treatment of the PI3K inhibitor LY294002 (0.8 or 1.6 µg, i.c.v.) 4 h before TMT counteracted protective effects (i.e., Nrf-2-dependent glutathione induction and pro-survival phenomenon) of rottlerin. Therefore, our results suggest that down-regulation of PKCδ and up-regulations of Nrf2-dependent glutathione defense mechanism and PI3K/Akt signaling are critical for attenuating TMT neurotoxicity. 相似文献
90.
Three‐Dimensional Echocardiographic Evaluation of Mitral Apparatus during Preload Manipulation in Patients with Hypertrophic Cardiomyopathy 下载免费PDF全文
Hyemoon Chung M.D. Ji Hyun Yoon M.D. Young Won Yoon M.D. Ph.D. Ji Young Chung B.N. Jung‐Joon Cha M.D. Jong‐Youn Kim M.D. Ph.D. Pil‐Ki Min M.D. Ph.D. Byoung‐Kwon Lee M.D. Ph.D. Bum‐Kee Hong M.D. Ph.D. Se‐Joong Rim M.D. Ph.D. Hyuck Moon Kwon M.D. Eui‐Young Choi M.D. Ph.D. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(8):1261-1269